Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)
| Status: | Recruiting |
|---|---|
| Conditions: | Anemia |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 12 - Any |
| Updated: | 3/27/2019 |
| Start Date: | October 2014 |
| End Date: | October 2020 |
| Contact: | Alycia Slaton, RN, CCRC |
| Email: | alycia.slaton@uhhospitals.org |
| Phone: | 216-286-0756 |
Sickle Cell Disease (SCD) Biochip': Towards a Simple and Reliable Way to Monitor Sickle Cell Disease
'Sickle-shaped' anemia was first clinically described in the US in 1910, and the mutated
heritable sickle hemoglobin molecule was identified in 1949. The pathophysiology of SCD is a
consequence of abnormal polymerization of sickle hemoglobin (HbS) and its effects on red cell
membrane properties, shape, and density, and subsequent critical changes in inflammatory cell
and endothelial cell function. Our goal is to understand the impact of CMA abnormalities in
SCD, by interrogating a number of recognized interactions in a range of clinical phenotypes.
To date, correlative studies in SCD, by us and others, have range between clinical reports,
based on tests, interventions, and chart review of individuals or groups of individuals and,
at the other extreme, identification of functional gene polymorphisms based on population
studies. The investigators wish to augment these studies through a systematic examination of
cellular membrane properties and activation status. Of hematologic disorders, SCD may be
unusually susceptible to such an examination.
heritable sickle hemoglobin molecule was identified in 1949. The pathophysiology of SCD is a
consequence of abnormal polymerization of sickle hemoglobin (HbS) and its effects on red cell
membrane properties, shape, and density, and subsequent critical changes in inflammatory cell
and endothelial cell function. Our goal is to understand the impact of CMA abnormalities in
SCD, by interrogating a number of recognized interactions in a range of clinical phenotypes.
To date, correlative studies in SCD, by us and others, have range between clinical reports,
based on tests, interventions, and chart review of individuals or groups of individuals and,
at the other extreme, identification of functional gene polymorphisms based on population
studies. The investigators wish to augment these studies through a systematic examination of
cellular membrane properties and activation status. Of hematologic disorders, SCD may be
unusually susceptible to such an examination.
Novel biofluidic chip technology can investigate surface characteristics that are typically
measured with conventional techniques, such as fluorescent activated cell sorting (FACS),
immunohistochemistry, or microscopic imaging methods. In FACS, cells of interest are
isolated, extensively processed, incubated with a fluorescent-labeled antibody and sorted by
optical recognition. In the proposed SCD biofluidic chip (SCD biochip), the interrogating
antibody coats the microchannel surface and captures the cell population(s) of interest,
without processing, incubation, or in vitro manipulation. The SCD biochip can also quantitate
cellular adherence to experimental biological surfaces that are comprised of subcellular
components. The SCD biochip is technically simple and experimentally flexible, whereby the
population of interest is retained on the chip and quantitated in situ. The microchip system
allows retrieval of viable isolated cells for potential downstream processing, analysis, and
in vitro culture.
measured with conventional techniques, such as fluorescent activated cell sorting (FACS),
immunohistochemistry, or microscopic imaging methods. In FACS, cells of interest are
isolated, extensively processed, incubated with a fluorescent-labeled antibody and sorted by
optical recognition. In the proposed SCD biofluidic chip (SCD biochip), the interrogating
antibody coats the microchannel surface and captures the cell population(s) of interest,
without processing, incubation, or in vitro manipulation. The SCD biochip can also quantitate
cellular adherence to experimental biological surfaces that are comprised of subcellular
components. The SCD biochip is technically simple and experimentally flexible, whereby the
population of interest is retained on the chip and quantitated in situ. The microchip system
allows retrieval of viable isolated cells for potential downstream processing, analysis, and
in vitro culture.
Inclusion Criteria
- Male or female ≥12 years of age at the time of consent (enrollment).
- Documentation Sickle Cell Disease, including HbSS or compound heterozygus HbSC- or
HbSβ- thalassemia diagnosis as evidenced by one or more clinical features.
- Written informed consent (and assent when applicable) obtained from subject or
subject's legal representative and ability for subject to comply with the requirements
of the study.
Exclusion Criteria
- Presence of a condition or abnormality that in the opinion of the Investigator would
compromise the safety of the patient or the quality of the data.
We found this trial at
1
site
Cleveland, Ohio 44194
Principal Investigator: Jane A Little, MD
Phone: 216-844-1272
Click here to add this to my saved trials
